BioPlus Acquisition Corp. Warrants
BIOSW
BIOSW was delisted on the 6th of October, 2023.
44 hedge funds and large institutions have $7.65M invested in BioPlus Acquisition Corp. Warrants in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 8 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
156% more capital invested
Capital invested by funds: $2.99M → $7.65M (+$4.66M)
10% less funds holding
Funds holding: 49 → 44 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Calamos Advisors
Naperville,
Illinois
|
+$25.6K |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$18.9K |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$6.72K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$6.39K |
| 5 |
CAC
Cowen and Company
New York
|
+$1.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$27K |
| 2 |
RA
Ramius Advisors
New York
|
-$16K |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$14K |
| 4 |
AGM
Alpine Global Management
New York
|
-$5K |
| 5 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$2K |
BIOSW Hedge Fund Activity: Q4 2022 in Review
44 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in BioPlus Acquisition Corp. Warrants (BIOSW) for Q4 2022, worth a combined $7.65M — up 156% from $2.99M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of BIOSW and 3 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was Calamos Advisors, opening a new position worth an estimated $25.6K. The largest seller was UBS O'Connor, exiting entirely with an estimated $27K sold.
- 44 institutional investors held BioPlus Acquisition Corp. Warrants (BIOSW) as of Q4 2022, down from 49 in Q3 2022.
- Funds reported $7.65M of BioPlus Acquisition Corp. Warrants stock for Q4 2022, up 156% quarter-over-quarter.
- 3 funds opened new BioPlus Acquisition Corp. Warrants positions in Q4 2022 and 8 closed out, a net change of -5 holders.
- The largest BioPlus Acquisition Corp. Warrants buyer in Q4 2022 was Calamos Advisors, an estimated $25.6K added.
- The largest BioPlus Acquisition Corp. Warrants seller in Q4 2022 was UBS O'Connor, an estimated $27K sold.
Based on aggregated 13F filings for Q4 2022.